- About Us
- Our People
- About You
- Which Service?
- Spotlight On
- Knowledge Hub
- Contact Us
Our reports focus on a variety of topics and provide in-depth, data-led analysis and commentary to identify trends and answer critical questions.Designed to offer unique insights our aim is to help businesses make strategic commercial decisions aligned to their goals and objectives in vital areas of IP.
EPO Opposition Trends in Engineering, Electronics and Software
In autumn 2020, we analysed more than 8000 opposition cases filed at the European Patent Office (EPO) over the last 12 years, studying the timelines for hundreds of engineering, electronics and software oppositions.
EPO Opposition Trends in the Life Sciences Sector
In spring 2019, Mewburn Ellis undertook 350 hours of research, analysing more than 5,000 opposition cases filed at the European Patent Office over the last ten years, studying the timelines for hundreds of life sciences oppositions both before and after the EPO’s opposition streamlining initiative.
Our report examines the role of patents in making innovative ‘green’ technologies into a reality as well as how the patent landscape can be used to identify opportunities for partnering, collaboration and investment.
Non-Traditional Pharmaceutical Trade Marks
In this special report, we explore the relevance of each type of non-traditional trade mark to the pharmaceutical sector, how they can be registered and enforced and the particular challenges brands will face along the way. We also explore the difficulties associated with attempts to register smell and taste marks successfully and what the future might hold for non-traditional trade marks in the pharma space.
Patent Landscape in Bioinformatics and Digital Health: a data-driven analysis
The words "digital health", "data driven" and "AI" have been on everyone's lips and in many headlines in the healthcare and life sciences sectors over the last couple of years. We set out to collect data on the patent landscape in the fields of bioinformatics and digital health, to see whether the growth we and our clients see in the field is reflected in the data and whether insights can be gained that will assist in designing better, more informed IP strategies.
Pharma and Life Sciences Patent Extensions in Europe
Over 60 countries provide extensions for pharma and life sciences patents – more than half of them in Europe. They’re incredibly important in helping to compensate for the years of delay in getting a product through clinical trials and regulatory reviews.
Software Inventions: UKIPO and EPO approaches to patent eligibility
It is well-known that it can be challenging to obtain patent protection for inventions relating to software in Europe. Indeed, it is common for software developers to assume that European patent protection is not available for their innovations.
The IP Guide for the Forward-Looking SME
Whether you are aiming for an exit strategy through investment or acquisition, or to grow and further establish your business, IP can play a key role. Perhaps you have some experience of IP but are you unsure if you're making the most of it? Perhaps you have no experience of IP and would like to understand how you could use it to your advantage?
Validation Strategies for Pharmaceutical Patents in Europe
The decision on where to validate a pharmaceutical European patent is a big one. With costs often precluding an “everywhere” approach for small- to medium-sized companies, research institutions and universities, it is necessary to choose from the long list of available countries.
The UK government and EU set out their agreed position on many of the issues related to intellectual property rights in the Draft Withdrawal Agreement. The UK government has also published papers explaining the approach in the event no agreement can be reached. Our consistent advice, which we still consider to be the best course of action, is that in order to protect brands in the EU, it remains appropriate to continue filing trade mark applications at the EUIPO, and that there is no legal necessity for dual filing in the UK.
The UK government and EU set out their agreed position on many of the issues related to intellectual property rights in the Draft Withdrawal Agreement. The UK government has also published papers explaining the approach in the event no agreement can be reached. Our consistent advice, which we still consider to be the best course of action, is that in order to protect brands in the EU, it remains appropriate to continue filing trade mark applications at the EUIPO, and that there is no legal necessity for dual filing in the UK.
The UK government and EU set out their agreed position on many of the issues related to intellectual property rights in the Draft Withdrawal Agreement. The UK government has also published papers explaining the approach in the event no agreement can be reached. Our consistent advice, which we still consider to be the best course of action, is that in order to protect brands in the EU, it remains appropriate to continue filing trade mark applications at the EUIPO, and that there is no legal necessity for dual filing in the UK.
Britain’s Brexit future may be complex and unclear. But with Mewburn Ellis, protecting your IP need not be. We are managing the process of converting all pending EU trade mark applications into UK trade mark applications for free.
Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.
Sign up to Forward: news, insights and features from Mewburn Ellis
Copyright © 2020 Mewburn Ellis. All rights reserved. Terms and Conditions & Online Privacy